HRP20100080T1 - Kombinacija koja sadrži kandesartan i rosuvastatin za liječenje ateroskleroze - Google Patents
Kombinacija koja sadrži kandesartan i rosuvastatin za liječenje ateroskleroze Download PDFInfo
- Publication number
- HRP20100080T1 HRP20100080T1 HR20100080T HRP20100080T HRP20100080T1 HR P20100080 T1 HRP20100080 T1 HR P20100080T1 HR 20100080 T HR20100080 T HR 20100080T HR P20100080 T HRP20100080 T HR P20100080T HR P20100080 T1 HRP20100080 T1 HR P20100080T1
- Authority
- HR
- Croatia
- Prior art keywords
- candesartan
- prevention
- combination according
- combination
- treatment
- Prior art date
Links
- 239000002053 C09CA06 - Candesartan Substances 0.000 title claims abstract 6
- 229960000932 candesartan Drugs 0.000 title claims abstract 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims abstract 3
- 229960000672 rosuvastatin Drugs 0.000 title claims abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 title claims 4
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 8
- 230000007211 cardiovascular event Effects 0.000 claims abstract 4
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims 6
- 239000002131 composite material Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Kombinacija koja se sastoji od kandesartana ili njegove farmaceutski prihvatljive soli i rosuvastatina ili njegove farmaceutski prihvatljive, naznačena time da se koristi za upotrebu pri prevenciji ili liječenju ateroskleroze. Patent sadrži još 8 patentnih zahtjeva.
Claims (9)
1. Kombinacija koja se sastoji od kandesartana ili njegove farmaceutski prihvatljive soli i rosuvastatina ili njegove farmaceutski prihvatljive, naznačena time da se koristi za upotrebu pri prevenciji ili liječenju ateroskleroze.
2. Farmaceutski kompozit, naznačen time da sadrži kombinaciju prema zahtjevu 1 uz dodatak farmaceutski prihvatljivog otapala ili nosača za upotrebu pri prevenciji ili liječenju ateroskleroze.
3. Upotreba kombinacije prema zahtjevu 1, naznačena time za proizvodnju lijeka za prevenciju ili liječenje ateroskleroze.
4. Kombinacija prema zahtjevu 1, naznačena time da je kandesartan u obliku kandesartan cilekstila.
5. Kombinacija kako je definirano u zahtjevu 1, naznačena time da se koristi kod prevencije kardiovaskularnih događaja, kao što su infarkt miokarda, pogoršanje angine, zastoj srca, moždani udar, kongestivno zatajenje srca i kardiovaskularna smrt.
6. Farmaceutski kompozit, naznačen time da sadrži kombinaciju prema zahtjevu 5 uz dodatak farmaceutski prihvatljivog otapala ili nosača za upotrebu pri prevenciji kardiovaskularnih događaja.
7. Upotreba kombinacije prema zahtjevu 5, naznačena time za proizvodnju lijeka za prevenciju kardiovaskularnih događaja.
8. Kombinacija prema zahtjevu 5, naznačena time da je kandesartan u obliku kandesartan cilekstila.
9. Kombinacija prema bilo kojem od zahtjeva 1, 4, 5, i 8, naznačena time da je kandesartan formuliran s hidroklorotiazidom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0322552.1A GB0322552D0 (en) | 2003-09-26 | 2003-09-26 | Therapeutic treatment |
PCT/GB2004/004120 WO2005030215A2 (en) | 2003-09-26 | 2004-09-22 | Therapeutic treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100080T1 true HRP20100080T1 (hr) | 2010-04-30 |
Family
ID=29286881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100080T HRP20100080T1 (hr) | 2003-09-26 | 2010-02-15 | Kombinacija koja sadrži kandesartan i rosuvastatin za liječenje ateroskleroze |
Country Status (29)
Country | Link |
---|---|
US (2) | US7932263B2 (hr) |
EP (1) | EP1673091B1 (hr) |
JP (1) | JP4841433B2 (hr) |
KR (1) | KR101129767B1 (hr) |
CN (1) | CN100515421C (hr) |
AT (1) | ATE451103T1 (hr) |
AU (1) | AU2004275567B2 (hr) |
BR (1) | BRPI0414724A (hr) |
CA (1) | CA2540102C (hr) |
CY (1) | CY1109814T1 (hr) |
DE (1) | DE602004024555D1 (hr) |
DK (1) | DK1673091T3 (hr) |
ES (1) | ES2336450T3 (hr) |
GB (1) | GB0322552D0 (hr) |
HK (1) | HK1090553A1 (hr) |
HR (1) | HRP20100080T1 (hr) |
IL (1) | IL174536A (hr) |
IS (1) | IS2729B (hr) |
MX (1) | MXPA06003353A (hr) |
NO (1) | NO335813B1 (hr) |
NZ (1) | NZ546162A (hr) |
PL (1) | PL1673091T3 (hr) |
PT (1) | PT1673091E (hr) |
RU (1) | RU2358737C2 (hr) |
SG (1) | SG145773A1 (hr) |
SI (1) | SI1673091T1 (hr) |
UA (1) | UA90249C2 (hr) |
WO (1) | WO2005030215A2 (hr) |
ZA (1) | ZA200602433B (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
US9260708B2 (en) * | 2009-09-29 | 2016-02-16 | Butamax Advanced Biofuels Llc | Yeast production host cells |
US20120239131A1 (en) * | 2011-03-15 | 2012-09-20 | Medtronic Vascular, Inc. | Methods and apparatus for treatment of aneurysmal tissue |
ES2622893T3 (es) * | 2011-12-09 | 2017-07-07 | Tratamiento de la pared arterial mediante la combinación de un inhibidor del SRAA y un inhibidor de la HMG-CoA reductasa | |
CN103479627A (zh) * | 2013-05-16 | 2014-01-01 | 武汉光谷百桥国际生物科技有限公司 | 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用 |
KR101771766B1 (ko) | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
CN109996545A (zh) * | 2016-11-15 | 2019-07-09 | 株式会社Lg化学 | 用于治疗2型糖尿病和糖尿病性血脂异常的药物复合物 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
US6004989A (en) * | 1990-04-27 | 1999-12-21 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
JP3883205B2 (ja) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | アンギオテンシン▲ii▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療 |
FR2741620B1 (fr) | 1995-11-28 | 1997-12-26 | Oreal | Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline |
KR19990087076A (ko) | 1996-04-05 | 1999-12-15 | 다께다 구니오 | 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물 |
JPH1081633A (ja) | 1996-07-16 | 1998-03-31 | Sankyo Co Ltd | 医薬組成物 |
GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
YU2700A (sh) | 1997-08-29 | 2002-06-19 | Pfizer Products Inc. | Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja |
GB9900339D0 (en) | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
GB0000710D0 (en) | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
AR022462A1 (es) | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
PL351279A1 (en) | 1999-04-13 | 2003-04-07 | Abbott Gmbh & Co Kg | Integrin receptor ligands |
RU2276997C2 (ru) | 1999-08-30 | 2006-05-27 | Санофи-Авентис Дойчланд Гмбх | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
CA2381926A1 (en) | 1999-08-31 | 2001-03-08 | Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
WO2001072706A1 (en) | 2000-03-28 | 2001-10-04 | Biocon India Limited | Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
AR030414A1 (es) | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
RU2298418C2 (ru) | 2000-04-12 | 2007-05-10 | Новартис Аг | Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза) |
US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
JP2002145770A (ja) | 2000-08-30 | 2002-05-22 | Sankyo Co Ltd | 心不全の予防又は治療のための医薬組成物 |
WO2002017913A1 (fr) * | 2000-08-30 | 2002-03-07 | Sankyo Company, Limited | Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque |
GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
WO2002058696A2 (en) * | 2001-01-26 | 2002-08-01 | Schering Corporation | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
EP1541175A3 (en) * | 2001-01-26 | 2006-04-12 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
WO2002095402A2 (en) * | 2001-04-18 | 2002-11-28 | Mcgill University | Individualization of therapy with hyperlipidemia agents |
SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre demented states |
GEP20084329B (en) | 2003-04-29 | 2008-03-25 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
JP2005126338A (ja) | 2003-10-21 | 2005-05-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 心不全治療剤 |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
US20060078615A1 (en) | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
-
2003
- 2003-09-26 GB GBGB0322552.1A patent/GB0322552D0/en not_active Ceased
-
2004
- 2004-09-22 KR KR1020067007973A patent/KR101129767B1/ko not_active IP Right Cessation
- 2004-09-22 PT PT04768663T patent/PT1673091E/pt unknown
- 2004-09-22 SI SI200431337T patent/SI1673091T1/sl unknown
- 2004-09-22 US US10/573,353 patent/US7932263B2/en active Active
- 2004-09-22 SG SG200806320-8A patent/SG145773A1/en unknown
- 2004-09-22 DE DE602004024555T patent/DE602004024555D1/de not_active Expired - Lifetime
- 2004-09-22 EP EP04768663A patent/EP1673091B1/en not_active Expired - Lifetime
- 2004-09-22 BR BRPI0414724-3A patent/BRPI0414724A/pt active Search and Examination
- 2004-09-22 NZ NZ546162A patent/NZ546162A/en not_active IP Right Cessation
- 2004-09-22 JP JP2006527488A patent/JP4841433B2/ja not_active Expired - Lifetime
- 2004-09-22 AT AT04768663T patent/ATE451103T1/de active
- 2004-09-22 WO PCT/GB2004/004120 patent/WO2005030215A2/en active Application Filing
- 2004-09-22 PL PL04768663T patent/PL1673091T3/pl unknown
- 2004-09-22 DK DK04768663.9T patent/DK1673091T3/da active
- 2004-09-22 MX MXPA06003353A patent/MXPA06003353A/es active IP Right Grant
- 2004-09-22 CN CNB2004800348230A patent/CN100515421C/zh not_active Expired - Lifetime
- 2004-09-22 RU RU2006113366/15A patent/RU2358737C2/ru not_active IP Right Cessation
- 2004-09-22 AU AU2004275567A patent/AU2004275567B2/en not_active Ceased
- 2004-09-22 CA CA2540102A patent/CA2540102C/en not_active Expired - Fee Related
- 2004-09-22 ES ES04768663T patent/ES2336450T3/es not_active Expired - Lifetime
- 2004-09-22 UA UAA200603434A patent/UA90249C2/uk unknown
-
2006
- 2006-03-23 IL IL174536A patent/IL174536A/en unknown
- 2006-03-24 ZA ZA200602433A patent/ZA200602433B/en unknown
- 2006-04-20 NO NO20061744A patent/NO335813B1/no not_active IP Right Cessation
- 2006-04-21 IS IS8421A patent/IS2729B/is unknown
- 2006-10-13 HK HK06111293.5A patent/HK1090553A1/xx unknown
-
2010
- 2010-02-15 HR HR20100080T patent/HRP20100080T1/hr unknown
- 2010-02-16 CY CY20101100154T patent/CY1109814T1/el unknown
- 2010-06-11 US US12/813,917 patent/US20110046119A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100080T1 (hr) | Kombinacija koja sadrži kandesartan i rosuvastatin za liječenje ateroskleroze | |
RS50377B (sr) | Inhibitori sistema renin-angiotenzin i njihova primena | |
HRP20040996B1 (hr) | Tablete visokog sadržaja lijeka | |
CL2003002731A1 (es) | Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe | |
GEP201706611B (en) | Amido compounds and their use as pharmaceuticals | |
WO2003066067A3 (en) | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases | |
CL2004000643A1 (es) | Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana. | |
RS52169B (en) | STABLE LAKVINIMOD PREPARATIONS | |
ATE158580T1 (de) | Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten | |
PT1572708E (pt) | Novos derivados de fluoroglicosidos heterociclicos, produtos farmaceuticos que contem estes compostos e sua utilizacao | |
CL2003002611A1 (es) | Compuestos derivados del acido tiofeno hidroxamico, 2-hidroxamida-5-[(aril o heteroaril)-disutituido-metil]-amida del acido tiofeno-2,5-dicarboxilico enantiomeros, composicion farmaceutica, procedimiento de preparacion, y su uso para el tratamiento d | |
JP2008515980A5 (hr) | ||
MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
DE602008003404D1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer | |
DE602004026903D1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält | |
FI3573620T3 (fi) | Koostumuksia kohonneen verenpaineen hoitamiseksi | |
WO2005004915A3 (en) | Compositions comprising meloxicam | |
HUP0203226A2 (hu) | Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény | |
IL276311B2 (en) | Methyllactam ring compound and its pharmaceutical use | |
EA200501231A1 (ru) | Применение дипиридамола в комбинации с ацетилсалициловой кислотой и антагонистом ангиотензина ii для предупреждения инсульта | |
DE60302951D1 (de) | Pyroglutaminsäure-salz von Amlodipin | |
ATE518842T1 (de) | Neue antagonistische derivate des vitronektinrezeptors, ihr herstellungsverfahren, ihre anwendung als arzneimittel und die pharmazeutischen zusammensetzungen, die sie enthalten | |
FR3040303B1 (fr) | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca | |
UY27628A1 (es) | "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco" | |
GB0325605D0 (en) | Combination of organic compounds |